Using a new animal model of Alzheimer’s disease, the study highlights a potential breakthrough in treatment strategies.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price target raised by equities research analysts at Wells Fargo ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target hoisted by Barclays from $55.00 to $56.00 in a note ...

Vistagen Therapeutics' Q3 2025 earnings reveal progress on Phase 3 trials for social anxiety drug fasedienol, innovative therapies, and strong ...

Fintel reports that on February 13, 2025, Scotiabank initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a Sector ...

"TGFB2 has emerged as a master regulator of immune suppression, not just in cancer but across multiple chronic diseases,” said Dr. Trieu. "Our work on OT-101 aims to neutralize TGFB2-driven resistance ...

Two new studies represent a big step toward developing innovative molecular therapies capable of disrupting the ...

Kuick Research Report Highlights Ongoing Developments In Molecular Switches Application Therapeutic Targets & Drug Delivery ...

Endometriosis, a prevalent gynecological condition, is characterized by the growth of endometrial-like tissues outside the ...

Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell ...

Truist raised the firm’s price target on Crispr Therapeutics (CRSP) to $120 from $100 and keeps a Buy rating on the shares. The company’s Q4 ...